VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
VolitionRx Limited (NYSE American: VNRX) said a real-world study with Hospices Civils de Lyon found its Nu.Q® Cancer assay (H3K27Me3-nucleosomes) in newly diagnosed lung cancer patients was associated with cancer stage and poorer outcomes. Volition reported an OS analysis using a cut-off and a Cox model stratifying low/high mortality risk, and said HCL clinical certification is complete and a France reimbursement dossier is planned.
How this was made
The 30-second read
Why it matters
The new study claims prognostic stratification (including ctDNA-negative patients) and management states HCL clinical certification is completed and a reimbursement dossier is planned under RIHN, with an admissibility timeline.
Market read
Traders may reprice commercialization probability for VNRX based on incremental clinical evidence and a near-term reimbursement dossier/admissibility timeline in France.
What to watch
The article does not provide effect sizes, statistical significance, or regulatory status for approval; peer review is pending, and the €50/test revenue assumption is not tied to confirmed volume or reimbursement rates.
Background
VolitionRx is developing blood-based epigenetic diagnostic/prognostic tests; this release focuses on Nu.Q® Cancer in newly diagnosed lung cancer and a France reimbursement pathway.
Ticker impact
VolitionRx reports new real-world evidence that its Nu.Q® Cancer assay prognostic biomarker (H3K27Me3-nucleosomes) stratifies lung cancer survival and risk.
Near-term: modest positive bias on biotech/diagnostics sentiment; medium-term: upside if reimbursement dossier acceptance and peer-review publication progress.
The release is a primary disclosure of new study results and a reimbursement submission timeline (admissibility within ~5 months after classification), which can move expectations, though it stops short of regulatory approval or reimbursement decision.
Market effects
Supports the broader epigenetic liquid biopsy/prognostic testing narrative; may raise attention on companion diagnostics and biomarker-driven patient stratification in oncology.
France is positioned as the first commercialization step via the RIHN reimbursement framework, potentially influencing sentiment toward French diagnostic adoption pathways.
If reimbursement is achieved in France, it can serve as a template for other countries and licensing discussions mentioned by management.
Counterpoint
Prognostic value and real-world evidence do not guarantee payer coverage or clinical adoption; reimbursement admissibility and eventual reimbursement determination remain uncertain.
Key entities
- companyVolitionRx Limited
NYSE American-listed epigenetics diagnostics company releasing Nu.Q® Cancer prognostic data and outlining France reimbursement steps.
- productNu.Q® Cancer Assay
Blood-based cancer assay measuring circulating H3K27Me3-nucleosomes to predict survival/progression risk.
- collaboratorHospices Civils de Lyon (HCL)
French university hospital system supporting clinical certification and collaboration on the study.
